Clinical trials: Neovascular Age-Related Macular Degeneration (NVAMD)
- Condition Neovascular Age-Related Macular Degeneration (NVAMD)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Neovascular Age-related Macular Degeneration
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
- Trial name
- NCT03362190
- Testing
- Avacincaptad Pegol, Lucentis
- Where
- 28 sites in United States, Hungary and 1 more
- Volunteers
- 64 people
- Sponsor
- Ophthotech Corporation
Neovascular Age-Related Macular Degeneration
Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment experienced subjects with neovascular…
- Trial name
- NCT05571267
- Testing
- Avacincaptad Pegol, Avastin, Lucentis
- Volunteers
- 1 people
- Sponsor
- IVERIC bio, Inc.
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination…
- Trial name
- AMARONE (NCT05919693)
- Testing
- Remigromig
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.